🇺🇸

US SEC Filing Intelligence

· daily

US Earnings Financial Results SEC Filings — July 20, 2026

The 13 filings reveal a bifurcated market: established operators like Domino's Pizza and MillerKnoll show steady but slowing growth, while a cluster of micro-cap companies (Alternus, Bakhu, Hestia, ANVI Global) continue to burn cash with no revenue or worsening deficits. FedEx's mixed results highlight a tale of two segments—strong parcel demand vs. a sharp freight downturn. A notable theme is the emergence of digital asset exposure in small caps: Pineapple Financial's balance sheet now holds $49.4M in digital assets, a transformative but high-risk allocation. Period-over-period trends show revenue growth at Park Aerospace (+18.9% YoY) and AB International (+103% YoY), but these are offset by margin compression at FedEx Freight (-970 bps) and MillerKnoll's declining organic orders. Insider activity is sparse across filings, limiting conviction signals, but capital allocation patterns reveal aggressive financing (PIPEs, preferred shares) among cash-strapped firms. The most critical development is FedEx's $738M spin-off costs, signaling a major restructuring that could unlock value or add execution risk.

13 high priority 13 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 20, 2026

This batch of 9 proxy filings reveals a market bifurcated between distressed SPACs and micro-cap companies facing existential threats, and a smaller cohort pursuing operational efficiencies. The most critical development is Origin Materials' unanimous board decision to dissolve and liquidate, a stark admission of failed strategy that sets a negative precedent for pre-revenue industrial tech. SPACs FutureTech II and Inflection Point V are both scrambling for extensions, with the former trading on OTC Markets and facing potential CFIUS scrutiny, highlighting systemic risk in the blank-check sector. Conversely, Sound Shore Fund and Bow River Capital are pursuing structural reorganizations to gain cost and compliance efficiencies, signaling a 'flight to quality' in fund management. Insider activity is notably absent across most filings, but CEO Steven Rossi's 51% voting control at Worksport is a significant governance red flag. The forward-looking catalyst calendar is dense with shareholder meetings in late August and early September 2026, creating a binary event window for several of these securities.

9 high priority 9 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 20, 2026

The IPO pipeline on July 20, 2026, is dominated by a mix of early-stage, high-risk micro-cap offerings and a transformative biotech merger, with no clear sector theme. The most material development is Standard BioTools' all-stock merger with Treeline Biosciences, a $2.5 billion deal that will result in a combined entity with a new name and contingent value rights, signaling a major strategic pivot. However, the pipeline is heavily weighted toward speculative, development-stage companies (RZ Wellness, Londonla Inc.) with no revenue, going-concern risks, and self-underwritten offerings, indicating a surge in low-quality filings. Period-over-period comparisons are largely absent as most filers have no prior operating history, but the lack of insider buying and the prevalence of going-concern warnings create a bearish undercurrent. The Grayscale Worldcoin ETF filing represents a niche but notable push into crypto-based ETFs, while the TCGX Acquisition Corp. SPAC offers a more traditional blank-check structure. Overall, the pipeline shows a bifurcation: one high-quality, high-value merger and a cluster of speculative, high-risk micro-cap IPOs that demand extreme caution.

7 high priority 7 total filings
· daily

US SEC Trading Suspension Halt Orders — July 20, 2026

The July 20, 2026, trading suspension landscape is dominated by a cluster of small-cap companies facing Nasdaq/NYSE non-compliance, with two new filings (Smart Powerr Corp. and SES AI Corp) adding to the existing TEN Holdings situation. The most critical development is Smart Powerr Corp.'s imminent delisting and suspension on July 21, 2026, after failing to appeal a bid price deficiency, which will force a move to the OTCQB market with severe liquidity implications. SES AI Corp has received a similar NYSE notice but has a six-month cure period, providing a more manageable timeline, while TEN Holdings has temporarily resolved its equity deficiency through a $6.6M offering but remains under Nasdaq monitoring. The common thread is a liquidity crisis among micro-cap issuers, with all three companies showing deteriorating financial metrics and no insider buying to signal management confidence. The aggregate data reveals a pattern of regulatory fatigue, where companies exhaust compliance plans and appeal processes before facing final suspension orders.

3 high priority 3 total filings
· daily

US Executive Officer Management Changes SEC — July 20, 2026

This digest of 21 SEC filings reveals a wave of executive and director changes across US-listed companies, with a notable concentration in the financial sector (banks and specialty finance) and life sciences. The period-over-period data from Investar Holding Corp shows a mixed earnings picture: net income declined 22.6% QoQ but surged 97.8% YoY, while net interest margin improved 8 bps. Forward-looking data from MultiSensor AI Holdings and USA Rare Earth provides key catalyst calendars, with the latter's CEO transition tied to a transformative merger. Insider activity is limited, but the appointment of a Galaxy Digital executive to Forward Industries' board signals deepening strategic ties. Capital allocation trends are sparse, though Chain Bridge Bancorp's enhanced incentive plans and Investar's operational conversion point to retention and integration focus. The most critical development is USA Rare Earth's leadership transition and pending merger, which carries high materiality and execution risk. Overall, the filings suggest a period of strategic repositioning and leadership refresh, particularly in banking and emerging technology sectors, with limited immediate financial impact from most changes.

21 high priority 21 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 20, 2026

The single filing in this stream, Sangamo Therapeutics' 8-K, confirms a definitive Chapter 11 bankruptcy and forced asset sale, marking a terminal event for the biotech. The company has no period-over-period comparisons, insider activity, or forward guidance, as the filing focuses solely on court-approved bidding procedures. The key development is the August 4, 2026 bid deadline and potential August 10 auction, creating a binary catalyst for distressed debt and asset buyers. The Nasdaq delisting and OTC trading underscore the collapse in equity value, with no recovery path for common shareholders. This filing represents a pure distressed asset play with no operational turnaround narrative, making it a high-risk, high-reward opportunity for specialized investors.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 20, 2026

The July 20, 2026, boardroom changes stream reveals a high volume of leadership transitions across 21 filings, with a notable concentration of CFO appointments and director additions. The most critical development is the leadership transition at USA Rare Earth, where CEO Barbara Humpton will retire effective October 1, 2026, coinciding with the anticipated closing of the Serra Verde combination—a high-stakes event with a materiality score of 9/10. The banking sector shows a pattern of strategic hires, with Hanover Bancorp appointing a new President with over 35 years of experience and Republic Bancorp experiencing a divisional president departure. Insider activity is limited, with no significant insider buying or selling detected across the filings. Forward-looking data is sparse, but MultiSensor AI Holdings' PSUs tied to 2029 revenue targets ($31.5M threshold, $45.0M target) provide a long-term performance benchmark. Capital allocation insights are minimal, though Forward Industries' deepening ties with Galaxy Digital through board appointments and existing agreements warrant monitoring. The overall sentiment is predominantly neutral, with only one positive sentiment (Lightwave Logic) and one negative sentiment (URSB Bancorp director departure).

21 high priority 21 total filings
· daily

USA Insider Trading Pulse — July 20, 2026

The July 20, 2026 insider trading pulse reveals a market characterized by cautious insider selling at elevated levels, particularly within the biotech and tech sectors, while notable insider buying is concentrated in small-cap and distressed names, signaling potential value opportunities. A significant cluster of 10b5-1 plan sales from multiple C-suite executives at Sea Ltd, MapLight Therapeutics, and Nexxen International suggests pre-planned, tax-related, or liquidity-driven selling rather than outright bearish sentiment, though the volume warrants monitoring. Conversely, a strong bullish signal emerges from Flora Growth Corp., where the Executive Chairman deployed $3.48M in a massive open-market purchase, and from a director at abrdn Healthcare funds who made coordinated, equal-value purchases across four closed-end funds, indicating a targeted value play. The day is dominated by neutral, non-discretionary events such as equity awards and tax-withholding sales, which do not reflect management conviction. Key themes include a concentration of insider selling in biotech (Incyte, MoonLake, MapLight), a pattern of insider buying in deeply undervalued small-caps (Flora Growth, 17 Education, SOLAI), and a notable lack of forward-looking guidance or capital allocation changes in the filings, limiting catalyst visibility. The most actionable intelligence lies in the contrast between the high-conviction buying in select micro-caps and the systematic, 10b5-1-driven selling in growth and biotech names, suggesting a rotation from momentum to deep value.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 20, 2026

The July 20, 2026 M&A landscape is dominated by SPAC turbulence and precious metals consolidation. Two SPACs (Compass Digital, DT Cloud Star) face imminent dissolution or delisting due to failed business combinations and regulatory non-compliance, while Drugs Made In America navigates a complex three-party merger with massive shareholder redemptions. In precious metals, Gold Resource Corp's acquisition by Goldgroup Mining creates a combined entity with diversified Mexican and US assets, signaling sector consolidation. Aterian's asset sale and CVR issuance represents a distressed restructuring, while Aptorum Group's merger with DiamiR and reverse split aims for a Nasdaq fresh start. Mawson Infrastructure's JV acquisition of a Texas power site for AI/HPC use highlights the growing convergence of energy and digital infrastructure. Insider activity is sparse but notable, with Oxley Bridge's board resignation and Compass Digital's unanimous shareholder vote for wind-up indicating management alignment with dissolution. The period-over-period data reveals no revenue or margin trends as most filings are event-driven 8-Ks, but capital allocation patterns show a clear preference for cash preservation and trust account redemptions over growth investment.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 20, 2026

This pre-market digest covers 50 filings, with a heavy concentration of 13F-HR institutional holdings updates (12 filings) that provide a snapshot of Q2 2026 positioning but lack period-over-period comparisons. The most actionable themes center on corporate actions: Jersey Mike's Subs is moving forward with a high-profile IPO (expected price range $21-$25), while DRC Medicine's SPAC merger with Ribbon Acquisition Corp is progressing (DRC holders to own ~85.78% of the combined entity). In the energy and mining space, Gold Resource Corp is being acquired by Goldgroup Mining, with the combined entity trading under 'GORO'. Domino's Pizza reported a sharp deceleration in US same-store sales (0.1% vs 3.4% a year ago), signaling a potential consumer spending slowdown. Flex Ltd. announced a major strategic spin-off of its Cloud and Power Infrastructure segment, achieving its FY27 margin target a year early. Insider activity is limited, but a controlling stake disclosure in Margaree Acquisition Corp (75% by Mark N. Tompkins) and a significant stake increase by Korea's NPS in Shinhan Financial Group (to 9.19%) are notable. The most critical risks include a financial restatement at Adapti, Inc. and a going concern warning from Spectral Capital Corp. The overall tone is mixed, with several high-conviction corporate events offset by operational headwinds in consumer-facing sectors.

11 high priority 39 medium 50 total filings
· daily

Biotech Small-Cap Approvals — July 18, 2026

This digest covers 7 FDA approvals from July 13-14, 2026, comprising 0 NMEs, 0 biosimilars, 0 label expansions, and 7 'Other' approvals (all generic/biosimilar entries). The dominant theme is generic erosion across multiple therapeutic areas, with no single therapeutic area clustering. The highest-conviction signal is the NME approval of GEDATOLISIB (REVTORPYK) by CELCUITY INC., granted Priority Review, representing a rare bullish catalyst in an otherwise neutral period. Key risk: the absence of NME approvals outside of CELCUITY's single event signals a weak innovation cycle for small-cap biotech sponsors during this window.

7 total filings
· daily

NME Blockbuster Approvals — July 18, 2026

The July 18, 2026, FDA approval period contains a single approval event: the NME approval of GEDATOLISIB (REVTORPYK) by CELCUITY INC., granted Priority Review. While classified as a FALLBACK-type approval, this represents a positive signal for CELCUITY’s execution capability and strengthens sentiment around small-molecule innovation outside of standard drug classes. No biosimilar or label expansion approvals were recorded, limiting differential competitive reads. The highest-conviction signal is from CELCUITY’s first NME approval, though the lack of disclosure on peak sales, exclusivity, pricing power, and market position tempers the near-term commercial thesis. The key risk remains the absence of commercial benchmarks (pricing, exclusivity length, market position) which are essential for peak sales modeling and competitive positioning.

1 total filings
· daily

Big Pharma Approvals — July 18, 2026

On July 18, 2026, the FDA issued 3 label expansion approvals, all classified as 'FALLBACK' type with bullish signals of moderate strength and materiality (5/10 each). There were zero NMEs, biosimilars, or standard label expansions in this period, indicating a quiet day for high-impact regulatory catalysts. The two approvals for SELPERCATINIB (RETEVMO, Eli Lilly) for separate indications signal a deliberate strategy to maximize the RET inhibitor's lifecycle, while the single ENLICITIDE CHLORIDE (Merck Sharp & Dohme) label expansion adds incremental optionality to Merck's pipeline. All three are rated broadly bullish, but the lack of NME approvals or biosimilar entries means there is no transformative commercial signal or competitive disruption present. Key risks include potential IRA exposure for SELPERCATINIB as a small molecule, and the limited available commercial data (all NOT_DISCLOSED) prevents full valuation assessment.

3 total filings
· daily

Orphan Drug Approvals — July 18, 2026

During July 18, 2026, the FDA issued two label expansion approvals for SELPERCATINIB (RETEVMO) by ELI LILLY AND CO, classified as 'Other' with no NME, biosimilar, or standard label expansion mix. Both approvals carry a bullish signal with moderate strength and materiality, suggesting incremental commercial value for LILLY's RETEVMO franchise, though specific indication details and peak sales estimates are NOT_DISCLOSED. The lack of NME or biosimilar approvals in this period limits sector-level innovation signals, but the dual approval for the same drug on the same day may indicate a strategic push to broaden label utility. The highest-conviction signal is the label expansion for SELPERCATINIB, which could support LILLY's oncology portfolio, but absence of disclosed clinical or market detail tempers conviction. Key risks include any potential confirmatory trial requirements or competitive pressure from other RET inhibitors like LOXO-292 in the RET-altered tumor landscape.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — July 18, 2026

This digest covers a single $120.6M civilian infrastructure contract awarded to H-K CONTRACTORS by the Department of Transportation/FHWA for the Yellowstone River Bridge in Wyoming. With zero defense-related awards, the period is entirely civilian, dominated by traditional heavy construction under a firm-fixed-price structure. The highest-conviction signal is neutral: the contract provides steady revenue visibility through November 2026, but $22.6M in remaining obligations and fixed-price risk on a multi-year project warrant monitoring. Key risk: execution delays or cost overruns on the fixed-price bridge replacement could compress margins for H-K CONTRACTORS.

1 total filings
· daily

DHS Homeland Security Contracts — July 18, 2026

The single contract digest for July 18, 2026, covers a $73 million DHS Homeland Security award to THOR SOLUTIONS LLC, a Service-Disabled Veteran-Owned Small Business, for U.S. Coast Guard engineering support services. The contract is entirely civilian, with no defense-related exposure, and carries a neutral signal strength of 5/10 and low materiality of 4/10. The highest-conviction signal is the stable multi-year revenue stream through 2027, but the fixed-price structure and small business set-aside introduce execution and margin risk. Key watch items include option exercises and THOR SOLUTIONS' ability to manage fixed-price cost pressures.

1 total filings
· daily

New Federal Contractors — July 18, 2026

This digest covers 7 new federal contracts totaling $1.09 billion, with only 1 defense-related award ($237.8M to KBR for NAVAIR cybersecurity), underscoring a civilian-heavy procurement stream. The dominant theme is stable, multi-year support services across NASA, DOT, DOL, DHS, and Education, with the highest-conviction signal being a $62M student loan servicing contract to Central Research Inc. (potential $150M through 2033) and a $84.9M Job Corps award to Management & Training Corporation, both offering low-risk, long-duration revenue. A key risk is that 5 of 7 contracts are fixed-price, exposing contractors to execution risk, while the absence of defense contracts limits exposure to NDAA-driven growth. Investors should watch option exercises on the Central Research and THOR SOLUTIONS contracts as near-term catalysts for revenue visibility.

7 total filings
· daily

New Drug Approvals (Original) — July 18, 2026

This digest covers 8 FDA approvals from July 13–16, 2026, characterized by a notable absence of NMEs and biosimilars, with all approvals classified as 'Other' (likely generic or label expansion). The period is dominated by 6 neutral-signal generic/biosimilar entries and 2 bullish signals. The highest-conviction event is the NME approval of GEDATOLISIB (REVTORPYK) by CELCUITY INC., granted Priority Review, signaling a potentially high-value oncology or rare disease asset despite undisclosed commercial details. The second bullish signal is a label expansion for ENLICITIDE CHLORIDE from MERCK SHARP AND DOHME LLC, reinforcing Merck's commercial execution. A key risk is the lack of NME or biosimilar designations in the data, which may reflect data classification issues; investors should verify the approval types for GEDATOLISIB and ENLICITIDE. The period shows no dominant therapeutic area theme, with approvals spanning anesthesia (PROPOFOL), oncology (AFATINIB), neurology (BRIVARACETAM), psychiatry (ALPRAZOLAM), and hematology (ELTROMBOPAG).

8 total filings
· daily

Significant Contract Modifications ($10M+) — July 18, 2026

This digest covers 7 significant contract modifications totaling $1.09 billion, with a striking 6-to-1 civilian-to-defense split, underscoring a non-defense-heavy procurement environment. The dominant theme is civilian agency infrastructure and services, led by NASA ($513.7M combined for AERIE AEROSPACE and Astrion Group) and the Department of Education ($62.1M for Central Research Inc.), signaling stable demand for lab support, engineering, and loan servicing. The highest-conviction signal is Central Research Inc.'s $150M potential student loan servicing contract through 2033, offering a long-term, merit-based revenue stream. A key risk is the fixed-price nature of 4 of 7 contracts, which exposes contractors like H-K CONTRACTORS and THOR SOLUTIONS to execution and cost-overrun risk, particularly in construction and engineering services.

7 total filings
· daily

Contract Deobligations Alert — July 18, 2026

This digest of 7 contracts totaling $1.09 billion reveals a heavily civilian-weighted procurement landscape, with only 1 of 7 awards (14%) defense-related, signaling a near-term lull in DOD contract activity. The dominant theme is stable, multi-year service support for civilian agencies, led by NASA ($513.7M combined to AERIE AEROSPACE and Astrion Group) and the Department of Education ($62.1M to Central Research Inc.). The highest-conviction signal is the bullish, long-term student loan servicing contract for Central Research Inc., which has a potential value of $150M through 2033, offering a durable revenue stream. A key risk is the concentration of awards to private companies (5 of 7), limiting public market exposure, and the fixed-price nature of several contracts (H-K CONTRACTORS, THOR SOLUTIONS, Central Research) which introduces execution risk in a rising cost environment.

7 total filings